EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhancing ERα-targeted compound efficacy in breast cancer threapy with ExplainableAI and GeneticAlgorithm

Zeonlung Pun iD, Qiaoyun Xue, Yichi Zhang

PLOS One · 2025

DOI: 10.1371/journal.pone.0319673 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Zeonlung Pun und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mathematics and Statistics, Huazhong Agricultural University, Wuhan 430000, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Estrogen Receptor alpha, Antineoplastic Agents. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer remains a major cause of mortality among women globally, driving the need for advanced therapeutic solutions. This study presents a novel, comprehensive methodology integrating explainable artificial intelligence (AI), machine learning models, and genetic algorithms to enhance the bioactivity and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties of compounds targeting estrogen receptor alpha (ER α ). By employing SHAP (SHapley Additive exPlanations) and LassoNet, we identified and refined 50 critical molecular descriptors from an initial set of 729, significantly influencing the prediction of bioactivity. The selected descriptors were systematically validated, bolstering the predictive robustness of our models, which demonstrated a mean coefficient of determination of 77 % for bioactivity and high accuracy scores of 90.2 % , 93.7 % , 89.5 % , 87.3 % , and 95.8 % for absorption, distribution, metabolism, excretion, and toxicity, respectively. Further optimization through genetic algorithms identified candidate compounds with superior bioactivity, achieving pIC 50 values as high as 10.05, surpassing the previously observed peak values in the dataset. These results underscore the potential of leveraging advanced machine learning and optimization techniques to accelerate the discovery of effective cancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsEstrogen Receptor alphaAntineoplastic AgentsHumansFemaleMachine LearningAlgorithmsArtificial Intelligence

Substanzen

Estrogen Receptor alphaESR1 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Mathematics and Statistics, Huazhong Agricultural University, Wuhan 430000, China.
  • Department of Mathematics and Statistics, University of Glasgow, Glasgow G128QQ, United Kingdom.
  • Faculty of Economics, Liaoning University, Shenyang, 110000, China.

ORCID-Profile: Zeonlung Pun

Zitieren

APA

Pun, Z., Xue, Q., & Zhang, Y. (2025). Enhancing ERα-targeted compound efficacy in breast cancer threapy with ExplainableAI and GeneticAlgorithm. PLOS One. https://doi.org/10.1371/journal.pone.0319673

Vancouver

Pun Z, Xue Q, Zhang Y. Enhancing ERα-targeted compound efficacy in breast cancer threapy with ExplainableAI and GeneticAlgorithm. PLOS One. 2025. doi:10.1371/journal.pone.0319673

BibTeX
@article{Pun2025,
  author = {Pun, Zeonlung and Xue, Qiaoyun and Zhang, Yichi},
  title = {Enhancing ERα-targeted compound efficacy in breast cancer threapy with ExplainableAI and GeneticAlgorithm},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0319673}
}
Kostenlos starten →